Skip links

Evolution of Exploratory Testing

Jump To Section

It’s easy to comprehend the first two steps as a rebellion of the imperative conception of testing and the way through defining its meaning as a separated technique.

Evolution of Exploratory Testing: From Rebellion to Normalization

The term “Exploratory Testing” evolved in the past years, software testing experts nowadays discuss the changes in its conception and evolution. James Bach and Michael Bolton described the timeline as a stairway with precise stages: ET 1.0 (Rebellion), ET1.5 (Explication), ET2.0 (Integration) and finally ET3.0 (Normalization).

It’s easy to comprehend the first two steps as a rebellion of the imperative conception of testing and the way through defining its meaning as a separated technique.

Integration leads to a continuum flux between the scripted testing and its exploratory sibling we have been experiencing in the last decade. This continuum fills in the gap, understanding the need for modeling reality in order to describe the behavior of the software and figuring the exploratory elements required to do so. On the other hand, if we are only applying exploratory testing, in our mental models there are many concepts already incorporated, “formalized” by our knowledge and experiences as testers; consciously or unconsciously we “plan” our test strategy.

ET 3.0 as a term

The step of Normalization is nothing less than the deprecation of the term “exploratory testing”. There’s no need to use the term “exploratory testing” because the essence of software testing is eminently exploratory and we should conceive activities like test case design, test automation at different levels, verification checklists, among others, as components and tools that assist the tester in the activity.

Let’s debate!

This leads to an open debate because this new conception of testing takes special significance in the context of agile methodologies. We are glad to hear your thoughts about it ???? Leave us a comment below! How is your conception of ET evolving?

Gonzalo Miraballes

Gonzalo Miraballes

Latest Reads


Suggested Reading

Ready to Unlock Yours Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes